Article
Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Therapeutic drug monitoring - 1 Oct 2013
Teh Lay Kek, Hamzah Sharina, Hashim Hazwanie, Bannur Zakaria, Zakaria Zainul Amiruddin, Hasbullani Zakaria, Shia John Kwong Siew, Fijeraid Henry, Md Nor Azmid, Zailani Mohd, Ramasamy Prabu, Ngow Harris, Sood Suneet, Salleh Mohd Zaki
Abstract excerpt
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to 5-FU toxicities and death. Association between serum concentration of 5-FU and its related toxicity has also been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.